EB Clinical Research Consortium (EBCRC) Grants
EB Clinical Research Consortium (EBCRC) Grants from EB Research Partnership fund clinical research to speed new therapies for Epidermolysis Bullosa at EBCRC sites.
Funder: EB Research Partnership
Due Dates: September 11, 2026 (EBCRC Grants application deadline)
Funding Amounts: One-year project funding; potential for annual renewal up to 5 years; indirect costs capped at 5%
Summary: Supports EB Clinical Research Consortium (EBCRC) site members conducting clinical research to accelerate therapies for Epidermolysis Bullosa.
Key Information: Only EBCRC site members are eligible; clinical trial work is strongly preferred.
Description
The EB Clinical Research Consortium (EBCRC) Grants, administered by the EB Research Partnership (EBRP), are designed to fund clinical research projects at EBCRC sites focused on advancing therapies for Epidermolysis Bullosa (EB). These grants emphasize projects with clear commercialization potential and immediate impact on patient quality of life, including new therapies, repurposed treatments, and development of research-enabling tools. EBRP employs a venture philanthropy model, requiring funded projects to consider commercial sustainability and alignment with ethical standards. The program aims to accelerate the path to market for promising EB therapies and tangible improvements in clinical care.
